Natural compound found in popular hot drink could protect brain against Alzheimer's, study finds
The research, published in the journal GeroScience, identifies two natural compounds, nicotinamide – a form of vitamin B3 – and an antioxidant found in green tea called epigallocatechin gallate, which help restore a key molecule that fuels energy production in brain cells.
Researchers found that nerve cells treated with these compounds not only experienced reversal of age-related decline but also an enhanced ability to clear away amyloid protein clusters, a hallmark feature of Alzheimer's.
'As people age, their brains show a decline in neuronal energy levels, which limits the ability to remove unwanted proteins and damaged components,' said Gregory Brewer, lead author of the study.
'We found that restoring energy levels helps neurons regain this critical cleanup function,' Dr Brewer said.
Researchers used a fluorescent molecule to track live guanosine triphosphate levels in neurons from aged mice showing signs of Alzheimer's.
Scientists found that the levels of energy-rich molecules GTP declined with age – particularly in the cells' mitochondria – leading to impaired elimination of cells with damaged components in a process called autophagy.
While it is known that autophagy, the cell's natural clean-up process, plays a key role in maintaining the health of tissues and organs, what part of ageing causes impairment in this process remains elusive.
When aged nerve cells were treated for just 24 hours with the study molecules nicotinamide and epigallocatechin gallate, the GTP levels were restored to levels typically seen in younger cells.
'Our results reveal age and AD-related neuronal GTP energy deficits that impair autophagy,' scientists wrote.
The molecules also improved energy metabolism within these cells, as well as efficient clearance of amyloid beta clusters.
'By supplementing the brain's energy systems with compounds that are already available as dietary supplements, we may have a new path toward treating age-related cognitive decline and Alzheimer's disease,' Dr Brewer said.
'This study highlights GTP as a previously under-appreciated energy source driving vital brain functions,' he added.
Researchers cautioned that more studies are required to find the best way to administer the compounds as treatment.
A recent study also showed that nicotinamide was not very effective when taken orally due to its inactivation in the bloodstream.
However, the findings point to promising strategies to rescue neurons in the brain's hippocampus from energy deficits related to ageing and Alzheimer's disease, researchers say.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging
Medscape
16 minutes ago
- Medscape
HER2+ mBC: Real-World Data Show Limits to Therapy
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman from City of Hope, and I'd like to discuss a very interesting paper recently published in The Oncologist, entitled "Treatment Patterns and Associated Outcomes among Patients with HER2 Positive Metastatic Breast Cancer in the United States: An Observational Cohort Study". One of the reasons that this type of analysis is so important is that it's real world, meaning that this is not selected patients on clinical trials. These are patients who are actually cared for in the community setting, where the vast majority of patients are cared for with cancer in the United States. And so, yes, we have clinical trials. Yes, they lead us to new therapies, new strategies. But, what is really happening? So this particular analysis comes from the US Flatiron Health Database patients treated from January 2013 to January 2021, who were followed through January of 2022. And as I noted, we're looking specifically here at HER2-positive metastatic breast cancer. These were patients who were in this particular database: 63% of these women were hormone receptor-positive with a median follow-up of 26 months; 56% of the patients received at least two lines of therapy for their metastatic, HER2-positive breast cancer, with 28% receiving three or more lines of therapy. Importantly, and I think critical to the real-world effects, about 25% of the patients unfortunately died or discontinued first-line therapy and did not get a second-line therapy during the analysis, despite the effectiveness of these therapies that we have. According to the patients didn't respond to the first-line therapy and did not have the opportunity to receive second-line therapy, about 50% of the patients who, in fact, went on and got second-line therapy, had to go to get a second-line therapy within the first year. Cleary, we are talking about the need for not only more therapeutic options, but more effective therapeutic options. Major progress has been made — patients with metastatic breast cancer are now living a number of years — but we need improved therapies that are both safe and that can prolong the quality of life as well as the duration of life. And I thank you for your attention.
Gizmodo
16 minutes ago
- Gizmodo
Stone Age People Brutalized Their Prisoners of War, New Evidence Suggests
When we think of Stone Age people, most imagine small communities living in caves, cutting into their most recent hunt with primitive tools, and imitating their environment with illustrative rock art. People during the Neolithic, however—the last stage of the Stone Age (around 9000 to 3300 BCE)—also waged wars and absolutely demolished their enemies. In a study published today in the journal Science Advances, researchers present horrific evidence suggesting that Neolithic people in northeastern France mutilated foreign invaders. Their findings might represent some of the earliest known indications of gruesome victory celebrations related to war. The international team of researchers analyzed skeletal remains and severed limbs from burial pits dating to between 4300 and 4150 BCE at two sites near Strasbourg, Achenheim and Bergheim. 'A total of 82 humans are analyzed,' they wrote in the study. Their analysis revealed 'differences between victims and nonvictims and suggest that the former were members of invading groups brutally killed, perhaps exposed and deposited in pits—together with trophies in the form of severed upper limbs—by local groups in what might be one of the earliest well-documented instances of martial victory celebrations in prehistoric Europe,' they explained. Previous research in the Upper Rhine Valley had already shown that this time period was marked by military invasions and cultural upheaval, but scientists didn't know whether the human remains at Achenheim and Bergheim were of locals or foreigners and/or prisoners of war. In addition to the severed upper limbs, the researchers also identified injuries such as skull fractures that had not healed. The team, including Valladolid University's Teresa Fernandez-Crespo, suggests these victims met violent ends during war. The individuals without these sorts of unhealed injuries, on the other hand, likely received a regular burial. To investigate the differences between those who were brutally killed and those who weren't, Fernandez-Crespo and her colleagues conducted isotopic analyses. By identifying ratios of isotopes—variants of the same element—in the remains, they discovered that, while the non-victims were locals, the victims of war violence came from other regions. According to the researchers, this indicates that the victims were likely invaders killed by locals. 'In view of their demise, it is probable that the identities of these victims can be attributed to socially remote, nonlocal enemies that became trophies or captives during battles or raids and that may have been considered by their captors as not properly 'human' and hence warranting such treatment,' the researchers explained. For once, the term 'overkill' applies literally.
